- Primary research
- Open Access
Bursopentin (BP5) induces G1 phase cell cycle arrest and endoplasmic reticulum stress/mitochondria-mediated caspase-dependent apoptosis in human colon cancer HCT116 cells
Cancer Cell Internationalvolume 19, Article number: 130 (2019)
Bursopentin (BP5) is a multifunctional pentapeptide found in the chicken bursa of Fabricius. Recent study indicated that BP5 significantly stimulates expression of p53 protein in colon cancer HCT116 cells. However, the effects and underlying mechanisms of BP5 on HCT116 cell proliferation remain largely unclear.
Analyses of cell viability, cell cycle arrest as well as apoptosis were performed to study the actions of BP5 on HCT116 cells. Western blot analyse was assayed to measure the cell cycle-related and apoptosis-related proteins. Specific siRNAs targeting IRE1, ATF-6, and PERK were used for IRE1, ATF-6, and PERK knockdown, respectively. Cellular reactive oxygen species (ROS) were detected using a H2DCF-DA green fluorescence probe. Cytosolic free Ca2+ concentrations and mitochondrial membrane potential (ΔΨm) were measured using Fluo-3 AM and JC-1 stains, respectively.
BP5 possessed strong inhibitory effects on the cell growth and induced apoptosis in HCT116 cells. Mechanistically, BP5 arrested the cell cycle at G1 phase by increasing p53 and p21 expression and decreasing cyclin E1-CDK2 complex expression. BP5 treatment dramatically activated the endoplasmic reticulum (ER) stress-mediated apoptotic pathway, as revealed by the significantly enhanced expression of unfolded protein response (UPR) sensors (IRE1α, ATF6, PERK) as well as downstream signaling molecules (XBP-1s, eIF2α, ATF4 and CHOP), and by the significantly altered the BP5-induced phenotypic changes in IRE1, ATF6, and PERK knockdown cells. Additionally, BP5-induced ER stress was accompanied by the accumulation of cytosolic free Ca2+ and intracellular ROS. Furthermore, BP5 treatment resulted in the increase of Bax expression, the decrease of Bcl-2 expression and the reduction of ΔΨm, subsequently causing a release of cytochrome c from the mitochondria into the cytoplasm and finally enhancing the activities of caspase-9 and -3. In addition, z-VAD-fmk, a pan-caspase inhibitor, markedly rescued BP5-induced cell viability reduction and reduced BP5-induced apoptosis.
Our present results suggest that BP5 has an anticancer capacity to arrest cell cycle at G1 phase and to trigger ER stress/mitochondria-mediated caspase-dependent apoptosis in HCT116 cells. Therefore, our findings provide insight into further investigations of the anticancer activities of BP5.
Human colon cancer is listed as one of the deadliest diseases and is the third leading cause of death from cancer . Current chemotherapeutic drugs are effective in the treatment of diseases, but they are related to severe clinical toxicities and the development of drug resistance of cancer cells. For this reason, it is a huge challenge for developing new cytotoxic drugs [2,3,4]. The use of naturally occurring substances have been considered to be an effective and less toxic approach in the treatment of various diseases, including many human cancers [5,6,7]. Among many chemical protective substances, the naturally occurring agents are well known for their structural diversity and have been playing an encouraging role in drug discovery . Therefore, several chemotherapeutic drugs developed from natural sources have been studied and are currently being used or are being investigated for cancer treatment.
Bursopentin (BP5, Cys-Lys-Arg-Val-Tyr) is a naturally occurring pentapeptide that is endogenously synthesized and found in the chicken bursa of the Fabricius (BF) . Several studies have suggested that BP5 is multifunctional. For instance, a previous study showed that BP5 can exhibits immunomodulator effects on T and B lymphocytes . It possesses the functions to stimulate humoral and cellular immune responses in chickens and mice [9, 10]. It was also found that BP5 has the ability to attenuate the immune function of dendritic cells, which are considered as a major target for immunomodulators . Moreover, BP5 has been demonstrated to possess antioxidant activity and protect living organisms from oxidative stress via decreasing intracellular ROS generation [12, 13]. It has been suggested that BP5 may be used as a new antioxidant therapy to combat the oxidative stress . More recently, it was reported that BP5 significantly enhances p53 luciferase activity and stimulates expression of p53 protein in HCT116 cells. By constructing a T7 phage display cDNA library, and using gene microarray, the differentially expressed genes associated with various pathways were identified, of which 25 pathways were involved in immune responses and oncogenic processes, including the p53 signalling pathway in DT40 cells . However, no information is available on the inhibitory ability of BP5 on the growth of HCT116 colon cancer cells.
Thus, the purpose of this study was to research whether BP5 has any ability to inhibit cancer cell growth and elucidate any mechanisms that might underlie this process in colon cancer HCT116 cells.
Materials and methods
BP5 was achieved from a commercial company (Bootech, Shanghai, China). The peptide purity of BP5 was greater than 98%. Using an E-Toxate Limulus LPS assay kit (Sigma), synthetic BP5 was assayed to rule out the possibility of lipopolysaccharide (LPS) contamination. Only LPS-uncontaminated peptides were used.
HCT116 cells and two immortalized normal cell lines (human keratinocyte HaCaT and mouse fibroblast NIH/3T3) were gained from the China Cell Bank of Type Culture Collection of (Shanghai, China). All these cells were incubated in DMEM with 10% foetal calf serum, 100 U/mL streptomycin (KeyGEN Biotech, Nanjing, China) and 100 U/mL penicillin (KeyGEN Biotech, Nanjing, China).
Cell viability assay
Cell viability was analysed using the CCK-8 Kit (Beyotime, Shanghai, China). First, HCT-116, HaCaT and NIH/3T3 cells were cultured in 96-well plates at a seeding density of 1 × 104 cells/mL. All cells were incubated with the indicated doses of BP5 for 24, 48 or 72 h after allowing 24 h for attachment. Then, the CCK-8 solution was added (10 μL/well) and the samples were cultured for another 2 h. The OD value of each well was analysed by an auto microplate reader (BioTek Instruments, USA). Observation of cell morphologic alterations were carried out with a Nikon Eclipse TS200 microscope (Nikon Corp., Tokyo, Japan).
Cell cycle assay
HCT116 cells were cultured with the indicated doses of BP5. After 24 h of incubation, all samples were collected, and the cells were gently fixed overnight by using 70% ice-cold ethanol. Next, all samples were further incubated with PI (40 μg/mL) (KeyGEN Biotech, Nanjing, China), Triton X-100 (0.1%) and RNase (0.1 mg/mL). After incubation at 37 °C for 30 min, all cultures were analysed using a flow cytometer (BD Biosciences, San Jose, CA, USA).
Cell apoptosis assay
HCT116 cells were cultured with the indicated amount of BP5. After 24 h of incubation, all samples were collected, and the cells were washed twice using cold PBS. Cells were then resuspended, treated with FITC annexin V, cultured at 4 °C for 15 min, and further incubated with PI. The double stained samples were then analysed using a FACS flow cytometer (BD Biosciences, San Jose, CA, USA).
Intracellular ROS assays
HCT116 cells (1 × 104/mL) were cultured overnight in glass plates. The cells were then treated with or without BP5 (2, 4, 8 mM) for 24 h. Samples were stained using 2,7-dichlorodihydrofluorescein diacetate (H2DCF-DA) fluorescent probe (Sigma-Aldrich, St. Louis, USA). At 37 °C in the dark, the stained cells were further cultured for another 30 min. In the presence of ROS, the nonfluorescent H2DCF-DA was turned into the fluorescent 2′,7′-dichlorofluorescein (DCF). The observation of cell images was carried out by a fluorescence microscope. ImageJ software was used to calculate the mean fluorescence intensity .
Measurement of cytosolic Ca2+
Fluo-3 AM (KeyGEN Biotech, Nanjing, China), the fluorescent Ca2+ indicator, was used to evaluate level changes of the cytosolic Ca2+. After cells were treated as described earlier, they were collected and stained with Fluo-3 AM. Following an additional 30 min incubation, all stained samples were immediately detected using flow cytometry.
Evaluation of mitochondrial membrane potential (ΔΨm)
Briefly, 24 h after BP5 treatment, all samples were harvested, and stained with JC-1 (KeyGEN Biotech, Nanjing, China). At 37 °C in the dark, the stained cells were further cultured for another 20 min. Then, the stained cells were centrifuged, removed the supernatant, resuspended in a 1× incubation buffer and analysed on a FACS flow cytometer (BD Biosciences, San Jose, CA, USA). Thereafter, all result analyses were carried out by using FlowJo v7.6 software (Tree Star Inc, Ashland, OR).
Small interfering RNA (siRNA) transfection
Specific siRNAs targeting IRE1, ATF-6, PERK and were used for IRE1, ATF-6, and PERK knockdown. IRE1, ATF-6 and PERK siRNAs were provided by GenePharma (Shanghai, China). Their targeting sequences were as follows: 5′-GCAAGAACAAGCUCAACUATT-3′ for IRE1; 5′-GUGAGCUACAAGUGUAUUATT-3′ for ATF-6; 5′-GUGGAAAGGUGAGGUAUAUTT-3′ for PERK. A non-targeting siRNA (si-NC, also synthesized by GenePharma) was employed as a negative control. Briefly, HCT116 cells were cultured and transiently transfected with 5 nM siRNAs using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). After an additional 4 h incubation, all samples were cultured with or without BP5 (8 mM) for 24 h. Then, all samples were prepared for the evaluation of cell viability, apoptosis and the protein expression levels of IRE1, ATF-6, and PERK.
Western blot analysis
HCT116 cells were homogenized in the lysate buffer, and the total proteins were prepared. Using a commercial mitochondria/cytosol fractionation kit (Beyotime, Shanghai, China), the cytosolic and mitochondrial proteins were obtained separately. The cell cycle arrest-related proteins of p53, p21, Cyclin E1, and CDK2; the ER stress-associated proteins of p-IRE1α, IRE1α, p-PERK, PERK, ATF6, XBP-1s, p-eIF2α, eIF2, ATF4, and CHOP; and the apoptosis-associated proteins of Bax, Bcl-2, cytoplasmic cytochrome c (Cyto Cyt C), mitochondrial cytochrome c (Mito Cyt C), caspase-9 and -3 as well as cleaved caspase-3, were all evaluated by western blot analysis.
Statistical analyses were performed using SPSS 17.0 (SPSS, Inc., Chicago, IL, USA) or GraphPad Prism 5.0 (GraphPad Software, San Diego, CA, USA) software. Data from the individual experiments were expressed as the mean ± SD. Statistical significance between the groups was determined with one-way analysis of variance (ANOVA) or Student’s t-test. P < 0.05 was considered to be a statistically significant difference.
BP5 inhibits HCT116 cell growth but has no significant effects on the proliferation of HaCaT and NIH/3T3 cells
To investigate the anticancer activity of BP5, CCK-8 assays were performed. Cell viability was investigated after HCT116 cells were incubated with various doses of BP5 (0.5–16 mM) for 24, 48 and 72 h. As shown in Fig. 1a, the cell viability of HCT116 was significantly suppressed in a dose- and time-dependent manner. Based on the CCK-8 assay results, we selected 2, 4 and 8 mM concentrations of BP5 for further experiments. We also detected the anti-growth activity of BP5 in HCT116 cells using optical photography. The microscopic examination showed that the morphology of BP5-treated cells was deformed, exfoliated, shrinking and dead, whereas dense cells were observed in the control groups. Meanwhile, the distorted cells were increased in a concentration-dependent manner in BP5-treated cells (Fig. 1b). Cell viability analyses of HaCaT and NIH/3T3 cells were also performed after cells were cultured with varying concentrations (0.5–16 mM) of BP5 for 72 h. The data showed that BP5 had no significant inhibitory influence on cell proliferation in HaCaT and NIH/3T3 cells (Fig. 1c). The microscopic examination showed dense organization and attachment in the BP5-treated HaCaT and NIH/3T3 cells (data not shown).
BP5 arrest cell cycle at the G1 phase
We then investigated whether BP5 has a potential to arrest cell cycle in HCT116 cells. Figure 2 shows that BP5 arrested cell cycle at G1 phase and this effect was dose-dependent in HCT116 cells. As the increase of BP5 concentration, the percentage of cells in G1 phase markedly increased, while the percentage of cells in G2/M phase decreased significantly.
BP5 induces cell apoptosis in HCT116 cells
It is well known that cell growth inhibition and apoptosis are closely linked to each other. This led us to further investigate whether BP5 could induce apoptosis in HCT116 cells. Compared with the control group, the BP5-treated groups showed significantly higher levels of apoptosis. Besides, our study also showed a significant dose-dependent increase of apoptosis after BP5 treatment in HCT116 cells (Fig. 3a, b).
BP5 induces cell cycle arrest through its effects on cell cycle protein expression levels
As showed in Fig. 4, p53 and p21 proteins were markedly elevated in the BP5-treated HCT116 cells when compared to those of the control cells. Meanwhile, in the BP5–treated HCT116 cells, the cycle arrest proteins Cyclin E1 and CDK2 were observed to decrease in expression in a dose–dependent manner.
BP5 activates ER stress and promotes ROS generation and cytosolic Ca2+ production
It was reported that ER stress exerts a vital role in the cell apoptotic progresses [17,18,19]. High levels of ROS and elevated cytosolic Ca2+ can trigger ER stress-induced apoptosis [20, 21]. Therefore, we measured ER stress pathway-associated proteins and assessed ROS generation as well as cytosolic Ca2+ elevation in BP5-treated or -untreated HCT116 cells. As presented in Fig. 5a, b, BP5 treatment lead to the upregulation of IRE1α, ATF 6 and PERK in HCT116 cells. After 3 h of BP5 treatment, we also observed the upregulation of the phosphorylation of IRE1α and PERK. IRE1α phosphorylation resulted in XBP-1s upregulation. Correspondingly, PERK phosphorylation resulted in phosphorylation of the eIF2a subunit, p-eIF2a activated ATF4, and ATF4 further increased CHOP. These increases in expression and phosphorylation persisted until the end of study at 24 h. In particular, the increase of CHOP indicated that ER stress boosted apoptosis in the cells. Additionally, as presented in Fig. 5c, IRE1, ATF6, and PERK depletion with specific siRNAs in BP5-treated cells significantly impaired the BP5-induced expression of IRE1, ATF6, and PERK. The data also revealed that inhibition of IRE1, ATF-6 and PERK in BP5-treated groups showed higher cell viability (Fig. 5d) and lower apoptosis (Fig. 5e) compared with the BP5-only groups. In addition, BP5 treatment also caused a significant increase in ROS generation (Fig. 6a, b) and cytosolic Ca2+ elevation (Fig. 6c, d) in a dose-dependent manner.
BP5 induces reduction of mitochondrial membrane potential (ΔΨ) and triggers mitochondria-mediated intrinsic apoptosis
Considering that mitochondria act as a central in the cell apoptotic progresses , we further evaluated ΔΨm and mitochondrial pathway-related proteins in BP5-treated HCT116 cells. As shown in Fig. 7a, b, BP5 treatment resulted in a significant higher green-to-red fluorescence ratio, indicating the number of cells with lower ΔΨm was increased. Bcl-2 family members serve as anti-apoptotic proteins and exhibit essential roles in controlling cell fate. On the other hand, proteins of Bax and Cyt C serve as pro-apoptotic proteins in cell apoptotic progression . In this study, accompanied with increase of Bax expression, expression of Bcl-2 was decreased when HCT116 cells were treated with BP5. Meanwhile, the release of Cyt C into the cytoplasm was raised. BP5 treatment also elevated levels of caspase-9 and -3 as well as cleaved caspase-3 (Fig. 7c, d). Additionally, Western blotting results also indicated that the ratio of cleaved caspase-3/total caspase-3 was significantly raised (Fig. 7e).
BP5 induces apoptosis in a caspase-dependent manner
Using zVAD-fmk (20 μM), a pan caspase inhibitor, to treat the HCT116 cells for 2 h before exposure to 8 mM BP5 for 24 h, we further examined whether BP5-induced apoptosis was caspase dependent. In this study, the influence of zVAD-fmk on cell viability in BP5- treated HCT116 cells were determined, and the effects of zVAD-fmk on BP5-induced apoptosis in HCT116 cells were also detected. As shown in Fig. 8a, b, treatment with zVAD-fmk had a little effect on the cell viability and cell apoptosis in HCT116 cells. In contrast, pretreatment with zVAD-fmk could significantly rescue the cell viability and reduce apoptosis in BP5-treated HCT116 cells.
In this research, we evaluated the effects of BP5, a natural pentapeptide found in the chicken bursa of Fabricius (BF), on cell proliferation and apoptosis in HCT116 cells, as well as the possible underlying signalling pathways and mechanisms. The results showed that BP5 suppressed cell viability by inducing G1 phase cell cycle arrest and apoptosis. Further investigation revealed that BP5 arrested cell cycle at G1 phase through p53 and p21 upregulation as well as Cyclin E1-CDK2 downregulation. Furthermore, BP5-mediated cell apoptosis was closely associated with the ER stress pathway via a mechanism involving activation of UPR sensors (IRE-1, PERK and ATF6) as well as their downstream signaling molecules (XBP-1s, eIF2α, ATF4 and CHOP), which was accompanied by increases in ROS generation and cytosolic Ca2+ production. Additionally, BP5 promoted cell apoptosis through the mitochondria-mediated apoptotic pathway via elevation of the Bax level and inhibition of the Bcl-2 level, leading reduction of ΔΨm, causing cytochrome c outflow from mitochondria and trigging caspase-9 and -3 activation. Finally, the apoptotic activation of BP5 was primarily associated with the caspase-dependent pathway.
Herein, we first assessed the anticancer ability of BP5 in HCT116 cells. The results showed that BP5 exerts anticancer potential on HCT116 cells by reducing the cell viability. It is well known that p53 exerts an important influence on the induction of cell cycle arrest . As a cell proliferation inhibitor, p21 acts as an important downstream target of p53 transcriptional regulation. By inhibiting the activities of Cyclin-CDK complexes, p21 has a vital effect on cell cycle arrest at G1 phase . Some reports have also revealed that G1 phase cell cycle arrest was controlled by Cyclin E-CDK2 complexes [25, 26]. In this research, our data showed that BP5 treatment dramatically elevated the levels of p53 and p21 and downregulated the levels of Cyclin E1 and CDK2 in HCT116 cells, all of which are associated with G1 phase cell cycle arrest. All data suggest that BP5 can inhibit HCT116 cell growth at least in part by modulating cell cycle progress.
Apoptosis is another main anti-cancer pathway that inhibit cancer cell proliferation in addition to cell cycle arrest. Hence, we researched whether BP5 could trigger apoptosis in HCT116 cells. Our data showed that BP5 treatment can significantly induce apoptosis in HCT116 cells. Thus, BP5 appears capable of inhibiting HCT116 cell growth also via an apoptotic mechanism. Therefore, we further researched the possible mechanisms underlying BP5-induced cell apoptosis, focusing our attention on the effects of BP5 on the ER stress-mediated apoptosis and the intrinsic mitochondrial apoptosis and the possible relationship between them.
There are lots of biochemical and physiological stimuli that can influence ER homeostasis and cause ER stress. These responses subsequently result in unfolded protein as well as misfolded proteins that are translocated into the ER . High levels or persisted activation of UPR signalling is associated with cell death . Therefore, the degree or duration of the UPR induced by sensors of ER stress, such as IRE-1, PERK and ATF6, seems to be more crucial for cell survival or death . Under ER stress, cleaved ATF6 (cleaved from membrane-bound ATF6) is entered into cell nucleus and regulates UPR associated gene transcription. IRE1α and XBP-1s (a cleavage target of p-IRE1a) play critical roles in the ER stress . The UPR also can induce phosphorylation eIF2α via PERK mediation. The p-eIF2α protein subsequently up-regulates the expression of ATF4 . During ER stress-induced apoptosis, ATF-4 expression can activate pro-apoptotic signalling pathways through initiation of its downstream transcriptional factor CHOP, which subsequently triggers ER stress-specific cascades for the induction of cell apoptosis [32, 33]. Thus, to investigate the possible signalling pathways involved in BP5-induced ER stress-related apoptosis, we screened UPR sensors (IRE-1, PERK and ATF6) as well as their downstream signalling molecules (XBP-1s, eIF2α, ATF4 and CHOP) in HCT116 cells. Our data revealed that activation of these ER stress-related proteins was associated with cell growth inhibition and apoptosis elevation. Additionally, to determine the nature of IRE-1, ATF6 or PERK activity in BP5-mediated ER stress, IRE1, ATF6, and PERK signaling were blocked by using specific siRNAs. Silencing IRE1, ATF-6 and PERK decreased the expression of IRE1, ATF6, and PERK induced by BP5, as well as altered the phenotypes of BP5-treated HCT116 cells. The data indicated that BP5 activated ER stress in HCT116 cells by intensifying the natural activity of IRE-1, ATF6 and PERK signalling. It is well known that there is a closely relation between oxidative stress and ER stress [34, 35]. Previous report also revealed that higher levels of intracellular Ca2+ contributes to ER stress . Considering that other researchers have revealed that ROS production can induce cell apoptosis via ER stress signalling  and that elevated-levels of cytosolic Ca2+ was deemed an important indicator of ER stress , we assessed whether ROS generation and cytosolic Ca2+ elevation were associated with BP5-induced ER stress. The data showed that treatment with BP5 caused a significant increase in intracellular ROS generation and cytosolic Ca2+ elevation. All the above data show that BP5 has an ability to induce ER stress and trigger ER stress-related pro-apoptotic signalling. Therefore, the results suggest that the ER stress signalling pathway is at least partially involved in BP5-induced HCT116 cell apoptosis.
To investigate whether the mitochondrial signalling pathway is associated with BP5-induced apoptosis, the Δψm and mitochondrial apoptosis-related proteins in HCT116 cells were measured. Our results indicated that BP5 treatment decreased the Δψm. The changes in apoptotic protein expressions is one of the pivotal events in the cell apoptosis involving mitochondrial dysfunction. The Bcl-2 family members regulates mitochondria-mediated apoptosis via delicate balance between the anti- and pro-apoptotic proteins, which plays a major role in controlling cell life and death . Under stress, Bax integrates into mitochondrial membrane, and then improves the membrane permeability and induce the outflow of cyto-chrome c by forming pores on the mitochondrial membrane . This mechanism permits cytochrome c to be released into cytoplasm and subsequently causes caspase activation . In this study, our data showed that BP5 treatment led to Bax upregulation, Bcl-2 downregulation, cytochrome c elevation in cytosol, and caspase-9 and -3 activation in HCT116 cells. All the results indicated that the BP5-induced apoptosis of HCT116 cells occurs also through the intrinsic mitochondrial signalling pathway.
It was well known that ER-mitochondria can exchange Ca2+ and mediate apoptotic signal transduction [42, 43]. Some reports have revealed that Bax not only interferes with the structure and function of mitochondria, but also enhances the storage of Ca2+ in ER, thus increasing the Ca2+ load [44,45,46]. Under ER stress, there is persistent release of Ca2+ from ER, causing an absorption of cation by the mitochondrial Ca2+ microdomain. This subsequently increases permeability of mitochondrial membrane and participates in decoding apoptotic signals mediated by Ca2+ . In some types of apoptosis, Bax-induced structural and functional changes in ER and increase of Ca2+ levels in mitochondria act as pivotal upstream signals for promoting release of cytochrome c . In addition, studies have shown that ROS is not only almost simultaneous with ER stress, but is a part of UPR components, and contributing to activation of pro-apoptotic UPR signalling. Within the cell, ROS regulates both of redox-sensitive enzymes and Ca2+ channels. For Ca2+ and ROS, there is a very delicate balance exists between the favourable and adverse effects on the mitochondria [34, 48]. Furthermore, the interaction between higher levels of ROS and higher concentrations of Ca2+ can induce a downregulation of Δψm and subsequently result in apoptotic activation [49, 50]. Consistent with previous reports, in the present study, our data revealed that BP5 treatment can also lead to increases in Bax, Ca2+ ions, and ROS in HCT116 cells. In this way, it plays a role in the mechanism behind the relationship of ER stress-mediated pathway and mitochondrial-mediated pathway in BP5-induced HCT116 cancer cell apoptosis. Additionally, in our study, pretreatment with z-VAD-fmk significantly rescued the BP5-induced decrease in cell viability and reduced the BP5-induced apoptosis in HCT116 cells. The data suggest that treatment of HCT116 cells with Z-VAD-fmk can inhibit BP5-induced caspase-dependent apoptotic cascades originating from both ER and mitochondria. Collectively, we conclude that the mechanism of BP5-induced ER stress and mitochondrial-mediated apoptosis is mainly related the caspase-dependent signalling pathway.
It is noteworthy that while BP5 induced cell cycle arrest and apoptosis in HCT116 colon cancer cells, it had significantly less cytotoxicity in normal human keratinocyte HaCaT cells and mouse fibroblast NIH/3T3 cells. Moreover, our lab found that BP5 had strong inhibitory effects on the growth of the colon cancer cell lines HT29 and SW620 (Additional file 1: Figure S1). The inhibitory actions of BP5 on HT29 and SW620 were also associated with the induction of cell cycle arrest at G1 phase (Additional file 2: Figure S2) as well as with the induction of cell apoptosis (Additional file 3: Figure S3). These characteristics strengthen the applicability of BP5 as a useful candidate reagent, which is worth additional study on its anticancer activity.
The possible signalling pathways and underlying mechanisms based on the analysis of our experimental results are summarized in Fig. 9, indicating that BP5 treatment can arrest cell cycle at G1 phase and induce ER stress/mitochondria-mediated caspase-dependent apoptosis in HCT116 cells. Since this is the first study to report that BP5 has an inhibitory effect on the growth of HCT116 cells, further mechanistic studies on the anticancer activities of BP5 are required in vitro and in vivo. Our present discoveries provide insight into the further investigation on the anticancer activities of BP5.
Availability of data and materials
The data generated or analysed during this study are available within the article.
unfolded protein response
reactive oxygen species
- Cyt C:
mitochondrial membrane potential
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.
Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D’Haens G, Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408–17.
Bach DH, Kim D, Bae SY, Kim WK, Hong JY, Lee HJ, Rajasekaran N, Kwon S, Fan Y, Luu TT, Shin YK, Lee J, Lee SK. Targeting nicotinamide N-methyltransferase and miR-449a in EGFR-TKI-resistant non-small-cell lung cancer cells. Mol Ther Nucleic Acids. 2018;11:455–67.
Bach DH, Luu TT, Kim D, An YJ, Park S, Park HJ, Lee SK. BMP4 upregulation is associated with acquired drug resistance and fatty acid metabolism in EGFR-mutant non-small-cell lung cancer cells. Mol Ther Nucleic Acids. 2018;12:817–28.
Singh RP, Agarwal R. Mechanisms and preclinical efficacy of silibinin in preventing skin cancer. Eur J Cancer. 2005;41:1969–79.
von Schwarzenberg K, Vollmar AM. Targeting apoptosis pathways by natural compounds in cancer. Marine compounds as lead structures and chemical tools for cancer therapy. Cancer Lett. 2013;332:295–303.
Shahabipour F, Caraglia M, Majeed M, Derosa G, Maffioli P, Sahebkar A. Naturally occurring anti-cancer agents targeting EZH2. Cancer Lett. 2017;400:325–35.
Phillipson JD. Phytochemistry and medicinal plants. Phytochemistry. 2001;56:237–43.
Li DY, Geng ZR, Zhu HF, Wang C, Miao DN, Chen PY. Immunomodulatory activities of a new pentapeptide (Bursopentin) from the chicken bursa of Fabricius. Amino Acids. 2011;40:505–15.
Li D, Xue M, Wang C, Wang J, Chen P. Bursopentin as a novel immunoadjuvant enhances both humoral and cell-mediated immune responses to inactivated H9N2 Avian Influenza virus in chickens. Clin Vaccine Immunol. 2011;18:1497–502.
Yin Y, Qin T, Yu Q, Yang Q. Bursopentin (BP5) from chicken bursa of fabricius attenuates the immune function of dendritic cells. Amino Acids. 2014;46:1763–74.
Li DY, Xue MY, Geng ZR, Chen PY. The suppressive effects of Bursopentine (BP5) on oxidative stress and NF-kB activation in lipopolysaccharide-activated murine peritoneal macrophages. Cell Physiol Biochem. 2012;29:9–20.
Qin T, Yin Y, Yu Q, Yang Q. Bursopentin (BP5) protects dendritic cells from lipopolysaccharide-induced oxidative stress for immunosuppression. PLoS ONE. 2015;10:e0117477.
Lam AT, Farago EP, Owen MC, Fiser B, Jojart B, Jensen SJ, Csizmadia IG, Viskolcz B. The effect of oxidative stress on the Bursopentin peptide structure: a theoretical study. Phys Chem Chem Phys. 2014;16:9602–9.
Guo X, Wang C, Li X, Wu T, Li D, Chen P. Antitumor mechanism of Bursopentin (BP5). Acta Microbiol Sin. 2015;55(2):235–45.
Bhardwaj M, Kim NH, Paul S, Jakhar R, Han J, Kang SC. 5-Hydroxy-7-methoxyflavone triggers mitochondrial-associated cell death via reactive oxygen species signaling in human colon carcinoma cells. PLoS ONE. 2016;11:e0154525.
Szegezdi E, Logue SE, Gorman AM, Samali A. Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Rep. 2006;7:880–5.
Tabas I, Ron D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat Cell Biol. 2011;13:184–90.
Sano R, Reed JC. ER stress-induced cell death mechanisms. Biochim Biophys Acta. 2013;1833:3460–70.
Verfaillie T, Rubio N, Garg AD, Bultynck G, Rizzuto R, Decuypere JP, Piette J, Linehan C, Gupta S, Samali A, Agostinis P. PERK is required at the ER-mitochondrial contact sites to convey apoptosis after ROS-based ER stress. Cell Death Differ. 2012;19:1880–91.
Mu D, Zhang W, Chu D, Liu T, Xie Y, Fu E, Jin F. The role of calcium, P38 MAPK in dihydroartemisinin-induced apoptosis of lung cancer PC-14 cells. Cancer Chemother Pharmacol. 2008;61:639–45.
Fulda S, Galluzzi L, Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov. 2010;9:447–64.
Zinkel S, Gross A, Yang E. BCL2 family in DNA damage and cell cycle control. Cell Death Differ. 2006;13:1351–9.
Di Leonardo A, Linke SP, Clarkin K, Wahl GM. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev. 1994;8(21):2540–51.
Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Zhang P, Dobrowolski S, Bai C, Connell-Crowley L, Swindell E, Fox MP, Wei N. Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell. 1995;6:387–400.
Liang YC, Lin-Shiau SY, Chen CF, Lin JK. Inhibition of cyclin-dependent kinases 2 and 4 activities as well as induction of Cdk inhibitors p21 and p27 during growth arrest of human breast carcinoma cells by (−)-epigallocatechin-3-gallate. J Cell Biochem. 1999;75:1–12.
Shen X, Zhang K, Kaufman RJ. The unfolded protein response—a stress signaling pathway of the endoplasmic reticulum. J Chem Neuroanat. 2004;28:79–92.
Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol. 2007;8:519–29.
Banerjee A, Ahmed H, Yang P, Czinn SJ, Blanchard TG. Endoplasmic reticulum stress and IRE-1 signaling cause apoptosis in colon cancer cells in response to andrographolide treatment. Oncotarget. 2016;7:41432–44.
Hetz C, Glimcher LH. Fine-tuning of the unfolded protein response: assembling the IRE1alpha interactome. Mol Cell. 2009;35:551–61.
Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. Science. 2011;334:1081–6.
Oyadomari S, Mori M. Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ. 2004;11:381–9.
Zhang X, Zhang HQ, Zhu GH, Wang YH, Yu XC, Zhu XB, Liang G, Xiao J, Li XK. A novel mono-carbonyl analogue of curcumin induces apoptosis in ovarian carcinoma cells via endoplasmic reticulum stress and reactive oxygen species production. Mol Med Rep. 2012;5(3):739–44.
Santos CX, Tanaka LY, Wosniak J, Laurindo FR. Mechanisms and implications of reactive oxygen species generation during the unfolded protein response: roles of endoplasmic reticulum oxidoreductases, mitochondrial electron transport, and NADPH oxidase. Antioxid Redox Signal. 2009;11:2409–27.
Banerjee A, Banerjee V, Czinn S, Blanchard T. Increased reactive oxygen species levels cause ER stress and cytotoxicity in andrographolide treated colon cancer cells. Oncotarget. 2017;8:26142–53.
Xu C, Bailly-Maitre B, Reed JC. Endoplasmic reticulum stress: cell life and death decisions. J Clin Invest. 2005;115:2656–64.
Qu K, Shen NY, Xu XS, Su HB, Wei JC, Tai MH, Meng FD, Zhou L, Zhang YL, Liu C. Emodin induces human T cell apoptosis in vitro by ROS-mediated endoplasmic reticulum stress and mitochondrial dysfunction. Acta Pharmacol Sin. 2013;34:1217–28.
Hsu YL, Wu LY, Kuo PL. Dehydrocostuslactone, a medicinal plant-derived sesquiterpene lactone, induces apoptosis coupled to endoplasmic reticulum stress in liver cancer cells. J Pharmacol Exp Ther. 2009;329:808–19.
Adams JM, Cory S. Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci. 2001;26:61–6.
Kuwana T, Newmeyer DD. Bcl-2-family proteins and the role of mitochondria in apoptosis. Curr Opin Cell Biol. 2003;15:691–9.
Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med. 2000;6:513–9.
Grande F, Parisi OI, Mordocco RA, Rocca C, Puoci F, Scrivano L, Quintieri AM, Cantafio P, Ferla S, Brancale A, Saturnino C, Cerra MC, Sinicropi MS, Angelone T. Quercetin derivatives as novel antihypertensive agents: synthesis and physiological characterization. Eur J Pharm Sci. 2016;82:161–70.
Pinton P, Giorgi C, Siviero R, Zecchini E, Rizzuto R. Calcium and apoptosis ER-mitochondria. Ca2+ transfer in the control of apoptosis. Oncogene. 2008;27:6407–18.
Gao X, Luo Z, Xiang T, Wang K, Li J, Wang P. Dihydroartemisinin induces endoplasmic reticulum stress-mediated apoptosis in HepG2 human hepatoma cells. Tumori. 2011;97:771–80.
Pinton P, Rizzuto R. Bcl-2 and Ca2+ homeostasis in the endoplasmic reticulum. Cell Death Differ. 2006;13:1409–18.
Chami M, Prandini A, Campanella M, Pinton P, Szabadkai G, Reed JC, Rizzuto R. Bcl-2 and Bax exert opposing effects on Ca2+ signaling, which do not depend on their putative pore-forming region. J Biol Chem. 2004;279:54581–9.
Nutt LK, Pataer A, Pahler J, Fang B, Roth J, McConkey DJ, Swisher SG. Bax and Bak promote apoptosis by modulating endoplasmic reticular and mitochondrial Ca2+ stores. J Biol Chem. 2002;277:9219–25.
Feissner RF, Skalska J, Gaum WE, Sheu SS. Crosstalk signaling between mitochondrial Ca2+ and ROS. Front Biosci. 2009;14:1197–218.
Xin J, Zhan Y, Liu M, Hu H, Xia L, Nie Y, Wu K, Liang J, Tian J. ApoG2 induces ER stress-dependent apoptosis in gastric cancer cells in vitro and its real-time evaluation by bioluminescence imaging in vivo. Cancer Lett. 2013;336:260–9.
Zhang J, Feng Z, Wang C, Zhou H, Liu W, Kanchana K, Dai X, Zou P, Gu J, Cai L, Liang G. Curcumin derivative WZ35 efficiently suppresses colon cancer progression through inducing ROS production and ER stress-dependent apoptosis. Am J Cancer Res. 2017;7(2):275–88.
We sincerely thank all the members who participated in this manuscript.
This work was supported by grants from the National Natural Science Foundation of China (No. 81303109, to H.X.).
Ethics approval and consent to participate
Consent for publication
All authors declare that there is no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.